129 related articles for article (PubMed ID: 37856738)
1. Comparison of Melanocyte-Associated Immunohistochemical Markers in Acral Lentiginous Melanoma and Acral Benign Nevi.
Kim JC; Choi JW; Kim YC
Am J Dermatopathol; 2023 Nov; 45(11):748-752. PubMed ID: 37856738
[TBL] [Abstract][Full Text] [Related]
2. Preferentially expressed antigen in melanoma immunohistochemistry as an adjunct for differential diagnosis in acral lentiginous melanoma and acral nevi.
Hu J; Cai X; Lv JJ; Wan XC; Zeng XY; Feng ML; Dai B; Kong YY
Hum Pathol; 2022 Feb; 120():9-17. PubMed ID: 34800527
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of PRAME expression by immunohistochemistry in subungual and non-subungual acral melanocytic lesions.
Rothrock AT; Torres-Cabala CA; Milton DR; Cho WC; Nagarajan P; Vanderbeck K; Curry JL; Ivan D; Prieto VG; Aung PP
J Cutan Pathol; 2022 Oct; 49(10):859-867. PubMed ID: 35794643
[TBL] [Abstract][Full Text] [Related]
4. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
Bahmad HF; Oh KS; Alexis J
J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299
[TBL] [Abstract][Full Text] [Related]
5. Comparative Analysis of PRAME Expression in 127 Acral and Nail Melanocytic Lesions.
Santandrea G; Valli R; Zanetti E; Ragazzi M; Pampena R; Longo C; Lai M; Piana S; Cesinaro AM
Am J Surg Pathol; 2022 May; 46(5):579-590. PubMed ID: 35275883
[TBL] [Abstract][Full Text] [Related]
6. Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms.
McBride JD; McAfee JL; Piliang M; Bergfeld WF; Fernandez AP; Ronen S; Billings SD; Ko JS
J Cutan Pathol; 2022 Mar; 49(3):220-230. PubMed ID: 34476825
[TBL] [Abstract][Full Text] [Related]
7. The utility of PRAME staining in identifying malignant transformation of melanocytic nevi.
Lohman ME; Steen AJ; Grekin RC; North JP
J Cutan Pathol; 2021 Jul; 48(7):856-862. PubMed ID: 33433032
[TBL] [Abstract][Full Text] [Related]
8. Acral lentiginous melanoma: an immunohistochemical study of 20 cases.
Kim YC; Lee MG; Choe SW; Lee MC; Chung HG; Cho SH
Int J Dermatol; 2003 Feb; 42(2):123-9. PubMed ID: 12709000
[TBL] [Abstract][Full Text] [Related]
9. Acral Spitz Nevi: A Clinicopathologic Study of 50 Cases With Immunohistochemical Analysis of P16 and P21 Expression.
Wiedemeyer K; Guadagno A; Davey J; Brenn T
Am J Surg Pathol; 2018 Jun; 42(6):821-827. PubMed ID: 29537991
[TBL] [Abstract][Full Text] [Related]
10. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
11. PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features.
Raghavan SS; Wang JY; Kwok S; Rieger KE; Novoa RA; Brown RA
J Cutan Pathol; 2020 Dec; 47(12):1123-1131. PubMed ID: 32700786
[TBL] [Abstract][Full Text] [Related]
12. Reflectance confocal microscopy features of acral lentiginous melanoma: a comparative study with acral nevi.
Cinotti E; Debarbieux S; Perrot JL; Labeille B; Long-Mira E; Habougit C; Douchet C; Depaepe L; Hammami-Ghorbel H; Lacour JP; Thomas L; Cambazard F; Bahadoran P;
J Eur Acad Dermatol Venereol; 2016 Jul; 30(7):1125-8. PubMed ID: 26428577
[TBL] [Abstract][Full Text] [Related]
13. Expression of p16 protein in acral lentiginous melanoma.
Hsieh R; Firmiano A; Sotto MN
Int J Dermatol; 2009 Dec; 48(12):1303-7. PubMed ID: 20415670
[TBL] [Abstract][Full Text] [Related]
14. PRAME Expression in Challenging Dermal Melanocytic Neoplasms and Soft Tissue Tumors With Melanocytic Differentiation.
Kline N; Menge TD; Hrycaj SM; Andea AA; Patel RM; Harms PW; Chan MP; Bresler SC
Am J Dermatopathol; 2022 Jun; 44(6):404-410. PubMed ID: 34991102
[TBL] [Abstract][Full Text] [Related]
15. PRAME expression in cutaneous melanoma does not correlate with disease-specific survival.
Parra O; Ma W; Li Z; Coffing BN; Linos K; LeBlanc RE; Momtahen S; Sriharan A; Cloutier JM; Wells WA; Yan S
J Cutan Pathol; 2023 Oct; 50(10):903-912. PubMed ID: 37430414
[TBL] [Abstract][Full Text] [Related]
16. Aberrant expression of HMB45 and negative PRAME expression in halo nevi.
Ruby KN; Li Z; Yan S
J Cutan Pathol; 2021 Apr; 48(4):519-525. PubMed ID: 33184871
[TBL] [Abstract][Full Text] [Related]
17. Performance of PRAME immunohistochemistry compared with that of c-Kit, c-Myc, or cyclin D1 for the diagnosis of acral melanocytic tumors.
Jung JM; Lee MY; Won CH; Chang SE; Lee MW; Lee WJ
Pathol Int; 2023 Jan; 73(1):27-36. PubMed ID: 36468840
[TBL] [Abstract][Full Text] [Related]
18. The diagnostic utility of PRAME and p16 in distinguishing nodal nevi from nodal metastatic melanoma.
See SHC; Finkelman BS; Yeldandi AV
Pathol Res Pract; 2020 Sep; 216(9):153105. PubMed ID: 32825968
[TBL] [Abstract][Full Text] [Related]
19. Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.
Googe PB; Flanigan KL; Miedema JR
Am J Dermatopathol; 2021 Nov; 43(11):794-800. PubMed ID: 33989214
[TBL] [Abstract][Full Text] [Related]
20. [Application of immunohistochemical staining of PRAME in differential diagnosis between melanoma and melanocytic nevus].
Du J; Yu WJ; Guo RP; Su J
Zhonghua Bing Li Xue Za Zhi; 2022 Jul; 51(7):621-626. PubMed ID: 35785832
[No Abstract] [Full Text] [Related]
[Next] [New Search]